07:46 AM EDT, 08/28/2024 (MT Newswires) -- Novartis ( NVS ) unit Novartis Pharma has signed a multi-target exclusive global licensing agreement and strategic collaboration with Lindy Biosciences to transition select Novartis ( NVS ) medicines to self-administered subcutaneous injections, Lindy Biosciences said Wednesday.

The medicines will be converted using Lindy Biosciences' microglassification suspension technology, enabling high-concentration biologics to be delivered in a single injection, according to the statement.

The deal includes a $20 million upfront payment to Lindy Biosciences, with up to $934 million in potential milestone payments, alongside tiered single-digit royalties on net sales, Lindy Biosciences.

Price: 120.13, Change: +0.29, Percent Change: +0.24